Physician profile
Michael G Day
NPI 1790768729
$3,540.67
in general payments reported to CMS, 2019-2025
30 companies · $90.91 in 2025
The $90.91 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $896 · 2020: $640 · 2021: $556 · 2022: $632 · 2023: $492 · 2024: $233 · 2025: $90.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $816.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $482.14 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $338.21 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.90 | 2019-2024 | Ofev, Tradjenta, Jardiance |
| Sanofi-Aventis U.S. LLC | $287.22 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $276.84 | 2019-2023 | Farxiga |
| Abbvie INC. | $254.79 | 2019-2023 | Ubrelvy, Synthroid, Vraylar |
| Abbott Laboratories | $209.06 | 2021-2023 | Freestyle Libre 3, Freestyle Libre |
| Lilly USA, LLC | $145.80 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amarin Pharma, INC. | $135.24 | 2019-2021 | |
| Amgen INC. | $132.61 | 2019 | |
| Pfizer INC. | $120.81 | 2019-2021 | |
| Genentech USA, INC. | $116.13 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $104.53 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.41 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $102.87 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $70.45 | 2023-2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $59.22 | 2023-2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $49.07 | 2021-2022 | |
| Eisai INC. | $39.52 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $32.18 | 2022-2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $31.48 | 2022 | |
| Allergan, INC. | $30.31 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $19.02 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $17.75 | 2021 | |
| Astellas Pharma US INC | $17.54 | 2023 | Myrbetriq |
| Endo Pharmaceuticals INC. | $16.79 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $16.62 | 2021 | |
| Ibsa Pharma INC. | $16.20 | 2025 | Flector, Tirosint, Licart |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.60 | 2020 | |
| Amneal Pharmaceuticals LLC | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.